Pristiq Vasomotor Symptoms Indication Set Back Until At Least 2009
This article was originally published in The Pink Sheet Daily
Executive Summary
Trial to confirm cardiovascular and hepatic safety of the SNRI will take at least 18 months to complete, Wyeth confirms.
You may also be interested in...
Pristiq Low Dose Shows Benefit In Treating MDD
Data on Wyeth’s investigational SNRI was submitted to FDA in August, with action expected in the first quarter.
Wyeth Will Pursue Maintenance Indication For Bifeprunox; Acute Treatment Is Unclear
FDA’s “not approvable” decision for both claims could set the antipsychotic’s potential approval timeframe back two years.
Wyeth Will Pursue Maintenance Indication For Bifeprunox; Acute Treatment Is Unclear
FDA’s “not approvable” decision for both claims could set the antipsychotic’s potential approval timeframe back two years.